Trilaciclib
Myelosuppression, Non-Human Animal
The First Affiliated Hospital of Xiamen UniversitySmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Myelosuppression, Non-Human Animal cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel The First Affiliated Hospital of Xiamen University | Phase 2 | B |
Myelo001 Myelo Therapeutics GmbH | Phase 2 | B |
Sacituzumab Tirumotecan The First Affiliated Hospital of Xiamen University | Phase 2 | CCC |
Sulanemadlin Aileron Therapeutics, Inc. | Phase 1 | CC |
Empegfilgrastim Moscow Clinical Scientific Center | Unknown | D |
Same molecule, other indications
Trilaciclib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →